65113-25-9

Basic information

• Product Name: 1-[4-(1H-Imidazol-1-yl)phenyl]methanamine
• Synonyms: 1-[4-(1H-imidazol-1-yl)phenyl]methanamine;1-[4-(4-methyl-1H-imidazol-1-yl)phenyl]methanamine;[4-(1H-Imidazol-1-yl)phenyl]methylamine;4-(1H-Imidazol-1-yl)benzylamine;(4-imidazol-1-ylphenyl)methanamine;[4-(1-imidazolyl)phenyl]methanamine
• CAS NO: 65113-25-9
• Molecular Formula: C₁₀H₁₁N₃
• Molecular Weight: 173.21
• Product Categories: Aminomethyl's;Phenyls & Phenyl-Het;Phenyls & Phenyl-Het
• Mol File: 65113-25-9.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 345.017 °C at 760 mmHg
• Flash Point: 162.461 °C
• Appearance: /
• Density: 1.164 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.623
• Storage Temp.: 2-8°C(protect from light)
• PKA: 8.84±0.10(Predicted)
• CAS DataBase Reference: 1-[4-(1H-Imidazol-1-yl)phenyl]methanamine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[4-(1H-Imidazol-1-yl)phenyl]methanamine(65113-25-9)
• EPA Substance Registry System: 1-[4-(1H-Imidazol-1-yl)phenyl]methanamine(65113-25-9)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 65113-25-9(Hazardous Substances Data)

Usage

General Description

1-[4-(1H-Imidazol-1-yl)phenyl]methanamine, also known as 1-(4-imidazol-1-ylphenyl)methanamine, is a chemical compound with the molecular formula C10H12N2. It is a derivative of methanamine and contains an imidazole ring, which gives it unique properties and potential applications. 1-[4-(1H-Imidazol-1-yl)phenyl]methanamine is commonly used as a building block in the synthesis of biologically active molecules, such as pharmaceuticals and agrochemicals. It may also have potential uses in the treatment of various medical conditions due to its interactions with biological systems and ability to modulate specific targets in the body. Its precise role and potential applications in medicine, however, are still being explored through ongoing research and development.

InChI:InChI=1/C10H11N3/c11-7-9-1-3-10(4-2-9)13-6-5-12-8-13/h1-6,8H,7,11H2

Upstream product

• 25372-03-6 4-(1H-imidazol-1-yl)benzonitrile 
• 789445-30-3 1-(4-(chloromethyl) phenyl)-1H-imidazole 
• 623-00-7 4-bromobenzenecarbonitrile 

Downstream Products

• 129872-54-4 1-[[[4-(1H-imidazol-1-yl)phenyl]methyl]amino]-3-(2-methylphenoxy)-2-propanol 
• 129872-55-5 N-{4-[2-Hydroxy-3-(4-imidazol-1-yl-benzylamino)-propoxy]-phenyl}-methanesulfonamide 
• 129895-59-6 (+/-)-1-<<<4-(1H-imidazol-1-yl)phenyl>methyl>amino>-3-(2-methylphenoxy)-2-propanol dihydrochloride 
• 1493764-08-1 2-(butylamino)-4-[(4-hydroxycyclohexyl)amino]-N-{[4-(1H-imidazol-1-yl)phenyl]methyl}pyrimidine-5-carboxamide 

Relevant articles and documents

Heterocyclic compound with Wnt signal path inhibitory activity and application thereof

The invention provides a heterocyclic compound with Wnt signal path inhibitory activity. The heterocyclic compound and chemically acceptable salt, isotope, isomer and a crystal structure thereof are provided with a structure shown as the general formula I (see the formula in the description). The invention further provides application of the heterocyclic compound with the Wnt signal path inhibitory activity. The heterocyclic compound with the Wnt signal path inhibitory activity serves as effective antagonist of a Wnt signal path, and can be used for treating or preventing diseases caused by abnormity of the Wnt signal path.

Synthesis and structure-activity relationship studies of N -benzyl-2-phenylpyrimidin-4-amine derivatives as potent usp1/uaf1 deubiquitinase inhibitors with anticancer activity against nonsmall cell lung cancer

Deregulation of ubiquitin conjugation or deconjugation has been implicated in the pathogenesis of many human diseases including cancer. The deubiquitinating enzyme USP1 (ubiquitin-specific protease 1), in association with UAF1 (USP1-associated factor 1), is a known regulator of DNA damage response and has been shown as a promising anticancer target. To further evaluate USP1/UAF1 as a therapeutic target, we conducted a quantitative high throughput screen of >400000 compounds and subsequent medicinal chemistry optimization of small molecules that inhibit the deubiquitinating activity of USP1/UAF1. Ultimately, these efforts led to the identification of ML323 (70) and related N-benzyl-2-phenylpyrimidin-4-amine derivatives, which possess nanomolar USP1/UAF1 inhibitory potency. Moreover, we demonstrate a strong correlation between compound IC50 values for USP1/UAF1 inhibition and activity in nonsmall cell lung cancer cells, specifically increased monoubiquitinated PCNA (Ub-PCNA) levels and decreased cell survival. Our results establish the druggability of the USP1/UAF1 deubiquitinase complex and its potential as a molecular target for anticancer therapies.

Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors

In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.